10/7
08:00 am
eq
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
High
Report
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
9/22
12:39 am
eq
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Medium
Report
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
9/17
12:22 pm
eq
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy [Yahoo! Finance]
Low
Report
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy [Yahoo! Finance]
9/10
08:00 am
eq
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
Low
Report
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
9/4
08:00 am
eq
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
8/28
08:00 am
eq
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
Low
Report
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
8/19
08:03 am
eq
Equillium, Inc. (NASDAQ: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Equillium, Inc. (NASDAQ: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
8/9
04:10 am
eq
Equillium GAAP EPS of $0.01 beats by $0.16, revenue of $13.9M beats by $7.57M [Seeking Alpha]
Medium
Report
Equillium GAAP EPS of $0.01 beats by $0.16, revenue of $13.9M beats by $7.57M [Seeking Alpha]
8/8
04:14 pm
eq
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights [Yahoo! Finance]
Medium
Report
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights [Yahoo! Finance]
8/8
04:01 pm
eq
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
Medium
Report
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
8/6
08:00 am
eq
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Low
Report
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease